ResAppDx-EU to Integrate on Telehealth App of Phenix, Stock price up by 110.145%

Be the First to Comment Read

ResAppDx-EU to Integrate on Telehealth App of Phenix, Stock price up by 110.145%

ResApp Health Limited (ASX:RAP) has entered into a joint development agreement (JDA) with Phenix Health Pty Ltd to integrate ResApp’s acute respiratory diagnostic test, ResAppDx-EU into Phenix’s telehealth smartphone app.

Telehealth is emerging as a vital tool in confronting the coronavirus pandemic, and Phenix is well positioned to deliver a significant service to the Australian community.

After this announcement, the stock of RAP closed the day’s trade at $0.145 soaring by 110.145%.

Disclaimer

Speak your Mind

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK